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Recurrent aphthous stomatitis is one of the most common diseases affecting the oral 
mucosa, and one of its variants is the most painful affliction of the oral mucosa. The 
lesion~ of recurrent aphthous stomatitis can be manifested as part of a broad spectrum of 
clinical disease ranging from the common minor aphthous ulcers to Behr;et's syndrome. 
Differential diagnosis, although not often difficult, must include many conditions capable 
of producing erosive and ulcerative oral mucosal lesions. The salient features of recurrent 
aphthous stomatitis suggest that it is a heterogeneous entity. Recent immunologic investi-
gations have focused attention on a possible immunopathogenesis and the evidence for this 
is reviewed. 
Recurrent aphthous stomatitis (RAS) is one of 
the most common diseases affecting the oral mu-
cosa, and one of its variants is the most painful 
affliction of the oral mucosa [1]. In the writings of 
William Shakespeare, some characters averred 
that they would be cursed with blisters of the 
tongue·for speaking an untruth: "If I prove honey-
mouth'd, let my tongue blister" (Paulina, The 
Winter's Tale 2.2.32). Juliet was not above cursing 
her nurse for shaming Romeo: "Blister'd be thy 
tongue for such a wish!" (Juliet, Romeo and Ju.liet 
3.2.90). These references to "blisters of the tongue" 
might well refer to RAS, as the tongue is com-
monly involved (Fig 1). 
Hippocrates ( 460 to 370 BC) is credited with the 
first use of the word "aphthai" in regard to oral 
diseases , although probably he was referring to 
thrush [2]. The first valid clinical description of 
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Abbreviations: 
ADCC: antibody-dependent cellular cytotoxicity 
BS: Beh~et's syndrome 
GSE: gluten-sensitive enteropathy 
HU: herpetiform ulcers 
IBD: inflammatory bowel disease 
MiAU: minor aphthous ulcer s 
MjAU: major aphthous ulcers 
RAS: recurrent aphthous ulcers 
RAS was published by Mikulicz and Kummel [3] 
in 1888. Sibley [4] provided the first description of 
RAS in the English language in the British Medi-
cal Jou.rnal in 1899. He described what is now 
recognized as minor aphthous ulcers a nd attrib-
uted their cause to psychic stress, naming them 
"neurotic ulcers." Sibley's index case was a dowa-
ger woman whose husba nd had died and left her 
a meager pension . She attempted to maintain the 
style of life to which she had been accustomed 
and found this very difficult. Because of the psy-
chologic stress of this situation and the coinciden-
tal RAS that she suffered, Sibley [4] hypothesized 
that the latter was a psychosomatic disease. Sut-
ton [5] described the first case of major aphthous 
ulcers in 1911 and coined the phrase "periadenitis 
mucosa necrotica recurrens," a lthough careful 
reading of his article reveals little mention of the 
glandular structures; indeed, he stated that the 
"deeper glands" were hardly affected. Both Cooke 
[6] and Lehner [7] pointed out the semantic confu-
sion surrounding Sutton's designation, and for 
this reason the term "major aphthous ulcers" has 
supplanted "periadenitis mucosa necrotica recur-
rens" in the r ecent literature. The third type, 
herpetiform ulcers, was described by Cooke [1] in 
1960. This author detailed the inability to discover 
a viral pathogen by cytologic, serologic, cultural , 
or histopathologic methods but advocated the ad-
jective "herpetiform" because it describes the clin-
ical appearance of the lesions. 
In the past several years, RAS has prompted 
considerable interest and research. The purpose 
of this review is to describe the clinical features of 
RAS, to discuss the differential diagnosis, and to 
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review recent investigations that suggest an im-
munopathogenesis for RAS. 
CLINICAL DESCRIPTION AND CLASSIFICATION OF 
RAS AND ITS VARIANTS 
Cooke [8] classified RAS into minor aphthous 
ulcers, major aphthous ulcers, and herpetiform 
ulcers (Table 1). Minor aphthous ulcers (MiAU) 
are recurrent crops of 1 to 5 punched-out ulcers 
usually affecting the "movable" or nonkeratinized 
oral mucosa (lips, buccal mucosa, mucobuccal and 
mucolabial sulci, and tongue) (Fig 2) . Major · 
aphthous ulcers (MjAU) are recurrent, large, 
chronic, and usually solitary ulcers that begin as 
nodules , destroy deep tissue, and heal with scar-
ring. MjAU affect the "movable" oral mucosa also 
as well as posterior mucosal surfaces (Fig 3). 
Herpetiform ulcers (HU) are recurrent, multiple , 
sh allow, pinpoint ulcers that may affect any part 
of the oral mucosa (Fig 4). MjAU and HU are 
distinctly less common than MiAU. 
Lehner [7] characterized these types from a 
study of 210 patients with recurrent oral ulcera-
tions. Table II describes the characteristics of 
these three variants and is partially derived from 
Lehner's study. 
Several studies of patients alleged to have RAS 
[2,9 ,10] have included from 8 to 13% of the patients 
with aphthous lesions of both the oral mucosa and 
genitalia. These patients had 1 of 3 types of 
recurrent oral and genital aphthous lesions: ulcus 
vulvae acutum, an incomplete Behc;et's syndrome, 
or aphthous stomatitis et vulvitis. 
Ulcus vulvae acutum was described by Lip-
schlitz [11] in 1913 in association with recurrent 
FIG 1. Aphthous lesions occurring on lateral border 
of tongue. Lesions such as these may have prompted 
Shakespeare to write about "blisters of the tongue." 
These minor aphthous ulcers are characterized by a 
central gray or yellow membrane and periphera l ery-
thematous h alo . 
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aphthous stomatitis. The entity was established 
by Berlin [12], who accepted two variants. The 
first variant was an acute , gangrenous, self-lim-
ited, nonrelapsing, ulcerative disorder of the vulva 
accompanied by an infectious disease, frequently 
enteric fever. This condition occurred in young 
females with a sudden onset, fever, and gangre-
nous ulcers of the labia minora with sharp bor-
ders, a dirty, firmly adherent membrane, and an 
erythematous halo. These lesions healed sponta-
neously with scarring in 2 to 3 weeks. 
The second variant that Berlin [12] accepted 
was a less acute, relapsing ulcerative disorder 
that he believed probably represented a forme 
fruste of Behc;et's syndrome (BS). These lesions 
were associated with RAS. Recurrent oral and 
genital aphthous ulcerations in men, although 
less often encountered, also represent the incom-
plete BS. 
Kierland (RR Kierland, personal communica-
tion) accepts a third variant called "aphthous 
stomatitis et vulvitis ." This disorder is character-
ized by recurrent oral and genital aphthous ulcers 
and persists for long periods without evolving into 
the complete BS. The vulvar or genital ulcers are 
not always associated with the recurrent oral 
aphthous ulcers but are present with enough fre-
quency to distinguish this group of patients from 
those with RAS. 
Recurrent oral aphthae, alone or in association 
with genital aphthae, can antedate the complete 
picture ofBS by months to years. The oral aphthae 
that occur in BS conform to any 1 of the 3 types 
described above; however, the incidence of HU 
and MjAU is increased in patients with this dis-
ease when compared with patients who have RAS 
FIG 2. Typical lesion of minor aphthous ulcer. Note 
occurrence of lesion in mucobuccal sulcus and charac-
teristic long oval conformation of lesions occurring in 
sulcus. 
TABLE I. Classification of recurrent aphthous stomatitis 
Type Author Year % of cases 11 
Minor aphthous ulcers Mikulicz & Kiimmel [3] 1888 80 
Major aphthous ulcers Sutton [5] 1911 8 
Herpetiform ulcers Cooke [1] 1960 8 
" The remaining 4% of patients with recurrent aphthous stomatitis fall into the other portion of the spectrum 
of the aphthosis diathesis (see text). 
Dec. 1977 
FIG 3. Large, nodular quality of Sutton's aphthae 
(major aphthous ulcers). 
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FIG 4. Diffuse distribution on oral mucosa of numer-
ous small aph thae that characterize herpetiform var-
iant of recurrent aphthous stomatitis. 
TABLE II. Characteristics of recurrent a.phthous stoma.titis" 
Characteristic MiAU MjAU HU 
Female-male ratio (% fe-
males) 
Age at onset (yr) 
Lesions 
1.3:1 (56) 
10-19 
< 10 
0.8:1 (44) 2.6:1 (73) 
10-19 20-29 
> 10 Size (mm) 
Site "Moveable oral mucosa" 
1-2 
Entire oral mucosa 
Lips, cheeks, tongue Lips , cheeks, tongue, 
palate, pharynx 
Number 1-5 1-10 10-100 
32 Healing with scarring 
(%) 
8 64 
" Derived, in part, from Lehner's [7] study. MiAU = minor aphthous ulcers; MjAU = major aphthous ulcers; 
HU = herpetiform ulcers. 
only [7]. A careful history and physical examina-
tion will often reveal the other characteristics of 
BS. The classic triad includes oral aphthous ul-
cers, ocular inflammation, and genital ulceration. 
With only 2 elements of the classic triad present, 
the addition of either synovitis or cutaneous vas-
culitis is sufficient for the diagnosis [13]. O'Duffy 
and Goldstein [14] would add meningoencephalitis 
to the latter group. As with other multisystem 
diseases, nonspecific symptoms such as fever , ma-
laise, arthralgias, and myalgias may be noted. 
Other reported manifestations of BS include su-
perficial and deep thrombophlebitis, epididymitis, 
colitis, pancreatitis, peripheral neuropathy, sub-
ungual infarctions, and malignant lymphoma 
[15]. The differential diagnosis should include er-
ythema multiforme, systemic lupus erythemato-
sus , Reiter's disease, Crohn's disease , and chronic 
ulcerative colitis. 
SALIENT FEATURES OF RAS 
In order to attempt to understand RAS and its 
variants with respect to pathogenesis , review of 
some salient features and associations may be 
helpful. The lesions of RAS may represent one 
disease, but they also may well represent mucosal 
manifestations of varying diseases . 
The results of several epidemiologic studies 
[2 ,7,10,16-18] reflect both the common occurrence 
ofRAS in the popula tion at large and the inability 
to determine a single etiologic agent. However, 
no random population studies have been con-
ducted to determine the true prevalence of this 
disease. The prevalence of RAS varies greatly 
with the demographic characteristics of the popu-
lation studied. Higher rates occur among middle-
class and upper-class professional students, inter-
mediate rates among outpatients of general medi-
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cal and dental clinics, and lower rates among 
indigent inpatients [16]. The range varies from 5 
to 60%. A reasonable estimate of prevalence would 
be 20% [16] . Several authors [10] report a 2:1 
female-to-male ratio of incidence, and Lehner [7] 
reported minor differences in sex incidence among 
the types of RAS. Sex incidences in his study are 
shown in Table II. RAS is typically a disease of 
young adults. . 
The stages of natural evolution of lesions of 
RAS have been synthesized by Stanley [19], who 
divides the natural history into the following 4 
stages: premonitory, preulcerative, ulcerative, 
and healing. Stage 1, the premonitory stage, lasts 
for up to 24 hours . This stage is characterized by 
tingling, tense, burning, painful, raw, or hyper-
esthetic sensations in the absence of any clinical 
changes. Some patients do not report a premoni-
tory stage. Stage 2, the preulcerative stage, lasts 
for 18 hours to 3' days . The painful sensation 
varies in intensity but is usually moderately se-
vere. Clinically, the aphthae begin as erythema-
tous macules or papules with slight induration. 
They are single or multiple, or circular or oval, 
depending on their location. The aphthae are 
surrounded by an erythematous halo and range 
from 2 to 20 or 40 mm in diameter. On the cheeks 
or lips, lesions are circular, whereas in the buccal 
or labial sulci or vestibule, oval lesions occur. 
Lesions overlying fibromuscular bands such as 
the frenum are exceptionally painful. 
Stage 3, the ulcerative stage, lasts from 1 to 16 
days. Early, these lesions are usually severely 
painful. Clinically, the papule or macule, which 
had begun to erode in the second stage, enlarges 
and ulcerates but remains a discrete lesion. The 
maximum size is usually attained 4 to 6 days 
after the onset; following this an indolent period 
sets in which persists until stage 4. The aphthae 
are gradually covered by a gray or yellow mem-
brane and are surrounded by a dusky, red halo. 
Two or 3 days later, there is an abrupt cessation 
of pain, leaving residual discomfort that correlates 
clinically with the appearance of the covering 
fibromembranous slough. It should be noted that 
this clinical characteristic must be considered in 
any study purporting to demonstrate therapeutic 
efficacy which uses reduction of pain as a criterion. 
Stage 4, the healing stage, lasts from 4 to 35 days. 
The lesions usually heal without scarring in 10 to 
21 days. Scarring occurs most commonly with 
MjAU and correlates with the depth of necrosis. 
The natural history of RAS is one of eventual 
remission. Sircus, Church, and Kelleher [2] found 
no significant differences with respect to sex in 
the length of time that the disease persisted. 
These authors stated that approximately 2 of 3 
patients with RAS will undergo remission within 
15 years, whereas one of three patients will con-
tinue to have RAS lesions for periods up to 40 
years . Lehner [7] found that most patients with 
MiAU had remissions by 15 years and that more 
than half of MiAU patients had remissions in less 
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than 5 years. The dura:tion of MjAU lesions was 
almost the opposite of that of MiAU lesions; al-
most two of three patients with MjAU (especially 
males) had activity for more than 15 years . Forty 
percent of patients with HU had activity for less 
than 5 years, 30% had activity for 6 to 15 years, 
and the remaining 30% had activity for more 
than 15 years. 
Other salient features include clinical observa-
tions about RAS such as association with the 
menstrual cycle and induction of lesions by 
trauma. 
The association of new RAS lesions with the 
premenstrual phase of the menstrual cycle has 
been reported [9,17]. The striking occurrence of 
remissions during the third trimester of preg-
nancy with prompt exacerbation after parturition 
lends credence to an endocrine association [9] . 
Dolby [20] demonstrated a consistently increased 
incidence of new ulcer formation during the 7 
days after ovulation. This was associated with 
increasing progesterone and decreasing estrogen 
levels. Bishop, Harris, and Trafford [21] reported 
considerable improvement in 30 of 33 women with 
premenstrual aphthae treated with systemic es-
trogens in doses sufficient to suppress ovulation. 
Carruthers [22] was able to demonstrate a benefi-
cial response with the use of oral anovulatory 
medications. This therapy was most successful 
with medications containing a high concentration 
of estrogen. Main and Ritchie [23J have studied 
the cornification index of the oral mucosa in rela-
tion to menstrual hormonal changes. The degree 
of cornification is low during the premenstrual 
phase (low estrogen), and this perhaps renders 
the oral mucosa more susceptible to trauma. The 
association of the hormonal changes and keratini-
zation lends credence to the role of endocrine 
factors in some patients. 
Trauma appears to play an important role in 
the induction of lesions of RAS. Clinically, self-
inflicted, incidental dental trauma is by far the 
most common aggravating factor [24]. Lesions 
occur in areas of the mouth most often subjected 
to trauma and least well keratinized. Lesions 
allegedly have been produced by dental manipu-
lation, but Ross et al [25] were unable consistently 
to induce lesions in susceptible patients by brush-
ing, pinching, needle puncture, and scalpel inci-
sion. Some edentulous sufferers of RAS have re-
missions while awaiting completion of their den-
tures and have exacerbations once they are fitted . 
The association of smoking and a decrease in 
the frequency and severity of RAS lesions in 
Dorsey's [26] patients lends credence to the concept 
of protection from trauma by oral hyperkeratosis. 
Ban6czy and Sallay [27] studied the oral cytology 
of a nonsmoking population, some with RAS, 
others with leukoplakia, and still others with no 
oral disease . They found significantly diminished 
keratinization in the patients with RAS when 
compared with those who had no oral disease and 
suggested that decreased keratinization was con-
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ducive to the occurrence of ulceration in patients 
with RAS. 
The most frequent sites of the lesions are the 
lips, cheeks, tongue, and sulci, where keratiniza-
tion is less well developed than in other areas of 
the oral mucosa. The studies of Main and Ritchie 
[23] on keratinization and fema le hormones and 
of Banoczy and Sallay [27] on the relative lack of 
hyperkeratosis in patients with RAS are pertinent 
to the role of trauma. One has little difficulty in 
consigning at least a permissive role to trauma in 
the induction of lesions of RAS. 
Several studies [2,18,28,29] have indicated a 
familial tendency in RAS. It is not unusual to 
find that 1 or more first-degree relatives of a 
patient with RAS also have RAS, but there is no 
definite evidence that this is genetic in origin. 
The overall prevalence is so high that a chance 
familial association would not be unreasonable; 
however, there may be an immunogenetic basis 
for these observations, as has been described in 
psoriasis [30,31], pemphigus vulgaris [32,33], and 
dermatitis herpetiformis [34]. 
The association of RAS with gastrointestinal 
disease has been recognized for years [35]. Accord-
ing to DuBois and van den Berghe [36], the term 
"sprue" is derived from the Dutch word for 
aphthous disease, "spruw." Truelove and Morris-
Owen [37] have emphasized the association of 
RAS with both idiopathic steatorrhea (celiac dis-
ease, nontropical sprue) and chronic ulcerative 
colitis . Sircus, Church, and Kelleher [2] believed 
that the incidence of RAS among the general 
population was so great that the association of 
RAS ·with gastrointestinal disease was probably 
of minor significance. 
Ferguson et al [38] performed jejunal biopsies 
in 33 patients with RAS and found 8 with flat 
mucosal architecture consistent with gluten-sen-
sitive enteropathy (GSE, celiac disease). All 8 
responded to a gluten-free diet with clinical remis-
sion of their aphthous lesions. This response was 
not dependent on concurrent administration of 
hematinics. Unfortunately , there was no differ-
ence in the RAS/GSE patients when compared 
with RAS patients with respect to gut-related 
symptoms. The authors stated that, as a group, 
the RAS/GSE patients had lower mean hemoglo-
bin and serum folate concentrations. 
Recently, Wray et al [39] screened 130 consecu-
tive outpatients with RAS for deficiencies of iron, 
vitamin ·B, 2, and folate . Twenty-three of the 130 
patients (17 .7%) were deficient in 1 or more fac-
tors , whereas 11 of130 (8.5%) age and sex-matched 
controls were deficient. The deficiencies were re-
placed, and all patients were followed for 1 year. 
Of the 23 RAS patients with deficiencies , 15 
showed complete remission and 8 showed definite 
improvement. Of the remaining 107, 33 had a 
remission or improved. Underlying diseases in-
cluded pernicious anemia, GSE, other malabsorp-
tion states, and other gastrointestinal diseases. 
RAS is associated with chronic ulcerative colitis 
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and Crohn's disease, collectively termed inflam-
matory bowel disease (IBD) [40]. Indeed, at times 
differentiation of IBD from BS can be difficult 
(RS Rogers III and JD O'Duffy, personal commu-
nications). 
The heterogeneous character of RAS can also 
be documented by the evidence gleaned from 
claims of success of various therapeutic modali-
ties . Often these successes [41,42] are not con-
firmed in other studies [43,44]. The recent enthu-
siasm for levamisole as a treatment for RAS 
provides evidence for the heterogeneity of the 
RAS population. Several small, uncontrolled stud-
ies [45,46] have reported the efficacy oflevamisole 
in some patients with RAS. A larger, open trial 
[47] of 50 patients resulted in 6% with complete 
remission, 56% with improvement, and 38% with 
no response. A double-blind, crossover trial has 
been carried out in 47 patients by Lehner, Wilton, 
and Ivanyi [48], who reported 64% positive re-
sponse and 36% nonresponders , of which 23 % had 
negative responses (worsening) . Agranulocytosis 
has developed during treatment with levamisole 
[49-51]. Whether this will limit the usefulness of 
the drug is not known at this time. 
Evidence gleaned from therapeutic trials suffers 
from several shortcomings. First is the variable 
history of RAS lesions- specifically, their variable 
duration and frequency of recurrence. This varia-
bility casts doubt on results in individual patients 
and requires very large numbers of patients for 
confident conclusions. Second is the natural reduc-
tion of pain that occurs during the ulcerative 
stage when the lesion is covered by a fibromem-
branous slough. Utilization of pain reduction as a 
parameter of efficacy is therefore highly suspect. 
Third is the paucity of adequately controlled stud-
ies . At a minimum, 33 of 107 patients will report 
a remission or definite improvement with local 
treatment, as has been demonstrated by the study 
of Wray et al. [39]. Long-term studies on large 
populations with double-blind, crossover provi-
sions are necessary . Finally, it appears from re-
viewing the literature on therapeutic intervention 
in RAS that almost anything rationally conceived 
will yield some benefit in some patients, including 
placebos. 
Clearly, the population of sufferers of RAS is 
not a homogeneous one. Some patients with RAS 
may show evolution into BS and some may have, 
or may acquire, gastrointestinal diseases. The 
differentially responsive populations among the 
levamisole-treated RAS patients may demonstrate 
different etiologic factors related to the RAS. With 
these considerations in mind, a review of the 
evidence that supports an immunopathologic con-
cept of the cause of RAS can be better appreciated. 
EVIDENCE FOR AN IMMUNOPATHOGENESIS FOR RAS 
Observations to support an immunopathogene-
sis for RAS can be gleaned from several sources. 
The association of RAS with ·certain diseases, the 
response of RAS to therapy, light and electron 
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microscopic observations, and in vitro immuno-
logic studies relative to streptococcal and oral 
mucosal antigen hypersensitivity are observations 
that lend credence to an immunopathogenesis for 
RAS. 
An immunopathogenesis has been proposed for 
IBD. This thesis is based on the demonstration of 
immunologic aberrations in both cellular and hu-
moral immunity [52] and also an antibody-depend-
ent cellular cytotoxicity mechanism demonstrated 
in vitro [53]. RAS lesions occur in IBD and often 
correlate with clinical activity of the disease 
[37,40]. BS is another disease for which an immu-
nopathogenesis is suspected [15,16,54,55]. RAS le-
sions are a hallmark of BS and commonly reflect 
the clinical activity of the syndrome . 
The dramatic resolution of typical RAS lesions 
in those RAS patients with GSE who were treated 
with a gluten-free diet [38] is another example of 
the correlation of RAS activity with the clinical 
activity of an underlying disease. GSE has been 
strongly associated with the HLA haplotype HLA-
B8 [56), and this possibly implicates an immuno-
genetic basis for GSE. Other diseases with strong 
HLA-B8 associations include Graves' disease, 
myasthenia gravis, dermatitis herpetiformis, and 
chronic active hepatitis [57], diseases for which 
an immunopathogenesis has been proposed. RAS 
is not notably associated with these diseases. In 
light of the familial tendency of RAS and its 
association with GSE, study of HLA patterns, the 
Ir region, and the major mixed lymphocyte culture 
determinants may provide insight into the strong 
family history of RAS and may provide immuno-
genetic information with respect to the pathogen-
esis ofRAS. 
The demonstration of a small group of RAS 
patients with iron deficiency and the dramatic 
response to iron therapy [39] is another association 
that might be pertinent to immunopathogenic 
mechanisms. Chandra [58] has shown that the 
number of T lymphocytes, the phytohemaggluti-
nin-induced transformation response, and cuta-
neous delayed hypersensitivity are reduced in 
iron-deficient subjects. These immunologic altera-
tions relate to serum iron and transferrin satura-
tion rather than to hemoglobin concentration. 
Furthermore, neutrophil function is impaired in 
iron deficiency. 
Finally, the response of some subjects with RAS 
to levamisole [45-48], a drug thought to possess 
immunopotentiating activity , lends further cir-
cumstantial evidence to an imrnunopathogenesis 
for RAS. . 
Pathologic observations of early RAS lesions 
also provide circumstantial evidence for this the-
sis. A cell-mediated immunopathogenesis has 
been suggested by the histopathologic appearance 
of early lesions of RAS [10,19,59] which fulfills 
the histologic criteria of Coe, Feldman, and Lee 
160] for a delayed hypersensitivity reaction. These 
criteria are (1) at least 3 clusters of mononuclear 
cells per cross section perivascularly or perineur-
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ally , (2) dispersed mononuclear cells in the dermis 
without obvious pattern, (3) polymorphonuclear 
leukocytes constituting less than 5% of the inflam-
matory infiltrate, and (4) absence of necrosis or 
smudging of the wall of venules. 
Recent investigations into self-tolerance and au-
toimmunity, reviewed with respect to thyroid dis-
ease by Allison [61], imply that such mononuclear 
infiltrates as described above may not necessarily 
imply T cell-mediated immunopathologic damage. 
The present evidence also implies that a B lym-
phocyte-mediated immunopathologic mechanism 
with antibodies, immune complexes, antibody-de-
pendent cellular cytotoxicity (ADCC), and K 
(killer) cells possibly play key roles. 
Additional support for a delayed hypersensitiv-
ity reaction is the electron microscopic demonstra-
tion of the presence of cytoplasmic phagosomelike 
bodies in mononuclear cells that invaded the epi-
thelium of early lesions of RAS [62]. This "inva-
sive-destructive" reaction pattern is considered by 
Waksman [63] as the forerunner of delayed hyper-
sensitivity damage to antigen-bearing epithelial 
cells. Electron microscopic studies by Houma (64] 
have demonstrated mononuclear cells in the pric-
kle cell layer of early RAS and BS lesions that 
resemble activated T or B lymphocytes as well as 
phagocytic mononuclear cells resembling macro-
phages. Other pathologic studies have not pro-
vided evidence for vasculitis in the submucosal 
vessels or immune complex-type damage to the 
epithelial cells or vessel walls in early RAS le-
sions, a lthough Lehner (personal communication) 
has reported the presence of immune complexes 
in the sera of patients with RAS and BS. 
Studies of serum immunoglobulins revealed 
mildly elevated levels of IgA and IgG in all 3 
types of RAS, with significant elevations in pa-
tients with MjAU. Serum complement levels (C3) 
have been normal. The incidence of autoantibodies 
to thyroid, gastric parietal cells, and nuclei did 
not differ from that in control populations. Cross-
reactions between oral mucosa and a variety of 
oral bacterial sonicates were negative except for 
the Lactobacillus acidophil us, the significance of 
which has not been investigated [65]. 
Lehner [65] hypothesized that oral epithelial 
antigens or some microbial cross-reacting antigens 
act as the stimulus for the immunologic responses 
that have been noted for RAS. Lehner [65] favored 
a cell-mediated immune response on the basis of 
the available data at the time of his hypothesis. A 
review of recent immunologic investigations focus-
ing attention on these two antigenic sources will 
permit an assessment of most of the evidence for 
an immunopathogenesis for RAS. 
Historically, the discovery of new microorga-
nisms has been reflected in the Jist of microbial 
agents evoked as etiologic culprits for RAS. 
Among these microorganisms studied and dis-
carded are Bacillus crassus, Mycobacterium tu-
berculosis, Candida albicans, Toxoplasma, My-
coplasma, and the herpes simplex virus. 
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The pleomorphic L-form of the alpha streptococ-
cus, Streptococcus sanguis (2AH:s HOT), became 
the thrust of the National Institute of Dental 
Research of the National Institutes of Health in 
the early 1960's, culminating with the Graykowski 
eta! [10] provocative JAMA article in 1966. Barile 
et a! [66] isolated pure cultures of an L-form from 
the base of lesions of RAS in three patients, and 
an identical organism was cultured from the blood 
of 1 of these patients during a severe exacerbation. 
In addition, cultures of biopsy specimens were 
also positive for the same organism. These authors 
[66] invoked the "L-form theory" to explain RAS. 
This theory presumes that the stable L-form is 
the dormant carrier state for recurrent infections 
and that it may live symbiotically in an intracel-
lular location. Under appropriate conditions, the 
stable L-form may revert to the pathogenic form 
or a bacterium. They hypothesized that antibiotics 
given to a patient for another disease could stim-
ulate conversion to the stable L-form and that 
trauma could cause the reversion to a pathogenic 
state. Stanley, Graykowski, and Barile [67] re-
ported that 93 % of lesions of RAS contained pleo-
morphic bacterial microorganisms as demon-
strated by histochemical stains. These same forms 
were found in 47% of autopsy specimens and 40% 
ofnonaphthous lesions. However, the pleomorphic 
forms are difficult to differentiate from parakera-
tin granules or mast cell granules by Giemsa 
stain. Tissue identification of these pleomorphic 
forms has not
1 
been established, although the au-
thors favored the alpha streptococcus as a source. 
These investigators [67] suggested that their data 
supported their "L-form theory." 
Graykowski, Barile, and Stanley [68] then in-
jected 10'; live transitional L-form organisms into 
rabbit skin and this produced a nodule in 12 
hours. Clinically and histopathologically the nod-
ule resembled a MjAU . The microbes were histo-
chemically visible in the lesions, and the orga-
nisms were cultured from the lesion. This was 
reproduced in guinea pig oral mucosa. 
Graykowski et al [10] then used heat-killed S. 
sanguis 2A organism in skin tests . They reported 
that a positive tuberculin-like response developed 
in 30 of 30 patients with RAS, whereas 1 of 4 
patients with lichen planus and 1 of 6 normal 
patients had positive reactions . 
Francis and Oppenheim [69] performed lympho-
cyte transformation tests using phytohemaggluti-
nin, smallpox vaccine, and heat-killed strepto-
cocci, including the S. sanguis prototype used by 
Graykowski et al [10] in their skin test studies. 
These authors found a diminished response of 
lymphocytes from RAS patients when compared 
with controls when the streptococcal 2A antigen 
was used. The lymphocytes of RAS patients were 
not hyporesponsive to the control antigens or the 
other heat-killed streptococcal antigens. No sup-
pressive plasma factors were found when the au-
thors removed autologous plasma and studied the 
lymphocytes in normal plasma. 
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Donatsky and Bendixen [70] studied streptococ-
cal hypersensitivity by the leukocyte migration 
technique [71] , which is an in vitro parameter of 
cellular hypersensitivity. These authors found 
that 8 of 17 patients with RAS but none of 13 
normal controls demonstrated cellular hypersen-
sitivity to the streptococcal 2A antigen. Donatsky 
[72] has recently extended his studies of in vitro 
cell-mediated immunity by the leukocyte migra-
tion technique. The migration index of patients 
with RAS differed significantly from that of nor-
mal controls and controls with other oral diseases 
when the lymphocytes were exposed to antigenic 
extracts of S . sanguis 2A, Streptococcus pyogenes 
M5, and adult human oral mucosa. In a further 
study, Donatsky [73] demonstrated that the leu-
kocyte migration index correlated with clinical 
activity of RAS when streptococcal 2A and adult 
human oral mucosa antigenic extracts were uti-
lized. However, other antigenic extracts, includ-
ing S. pyogenes M5, did not show clinical correla-
tion. 
Donatsky and Dabelsteen [74] examined sera of 
RAS patients and controls for the presence of 
humoral antibodies to the same streptococcal 2A 
antigen by means of a double-layered indirect 
immunofluorescent technique. Antibodies to the 
2A antigen were demonstrable in both popula-
tions, but the mean end-point titers were signifi-
cantly higher among the RAS patients when com-
pared with controls. However, Donatsky [73] was 
unable to demonstrate differences in end-point 
titers in antibodies to streptococcal 2A, streptococ-
cal M5, and adult human oral mucosa antigens 
with respect to clinical activity of the RAS. 
Thus, there is strong evidence that a hypersen-
sitivity response to the streptococcal 2A antigen 
exists . The positive delayed hypersensitivity skin 
tests, the positive in vitro leukocyte tests corre-
latea with RAS disease activity , the hyporespon-
sive lymphocyte transformation tests , and the 
evidence of humoral antibody to the streptococcal 
2A antigen may indicate that a specific subset of 
lymphomononuclear cells is implicated in the hy-
persensitivity response and that mechanisms such 
as ADCC may be pertinent. 
The studies of Donatsky [72,73] indicate an in 
vitro immunologic response to an adult human 
oral mucosa antigen extract as well as to the 
streptococcal 2A antigen. Oral mucosal antigens 
have been studied by other investigators as a 
possible stimulus for the putative autoimmune 
pathogenesis of RAS. Oshima et al l54] demon-
strated antibody directed against an oral mucosal 
antigen by the tanned-cell hemagglutination tech-
nique in 17 of 40 patients with BS. A similar 
antibody was found in the sera of 4 of 25 control 
patients and in none of 18 healthy controls. Twelve 
of the 17 patients with antimucosal antibodies 
had oral lesions. The authors stated that the titer 
was higher before attacks of BS and that it de-
clined with remissions. 
Humoral immune responses also have been im-
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plicated by the demonstration of antimucosal anti-
bodies to human fetal oral mucosa by the tanned-
cell hemagglutination technique by Lehner 
[55,75]. This author found that the sera of 75% of 
237 patients with MiAU and MjAU, 20% of pa-
tients with HU, and 86% of 21 patients with BS 
contained the antimucosal antibodies. Of controls, 
10% possessed the antimucosal antibodies. These 
antibodies were found predominantly in the IgM 
class and to a lesser extent in the IgG class of 
antibodies. However, immune absorption studies 
demonstrated a lack of species or tissue specificity, 
and the antibody titers did not correlate with the 
course or the severity of the disease [76]. Lehner's 
study differs from that of Oshima et a! [54], who 
noted correlation of titers with disease activity. 
Donatsky [73] and Donatsky and Dabelsteen [77] 
confirmed Lehner's work [55, 75]. 
Using homologous adult human buccal mucosal 
tissue from an RAS patient and from a normal 
control subject as substrates for the indirect im-
munofluorescent test, Donatsky and Dabelsteen 
[77] studied the sera of 24 patients with RAS and 
24 normal controls. The mean value of the end-
point titer of the controls (1:2) was lower than 
that of the RAS group (1:8). A positive reaction 
was the apple-green fluorescence of the cytoplasm 
of the stratum spinosum cells. Rogers, Movius, 
and Jordon [78] have been unable to demonstrate 
an immunofluorescent pattern with the use of 
sera in a 1:10 dilution 'f:rom RAS patients and 
monkey esophageal or human gingival mucosal 
substrates for the indirect immunofluorescent 
test. 
Lehner [59] has demonstrated binding of fluo-
rescein-conjugated immunoglobulins to oral mu-
cosal tissue of 10 of 19 patients with MiAU, MjAU, 
and BS by the direct immunofluorescent tech-
nique. The third component of complement was 
bound in 5 of 19. This author also demonstrated 
binding of patients' sera to autologous oral mu-
cosal tissue specimens in 10 of 19 patients by a 
modified indirect immunofluorescent technique. 
The use of normal control oral mucosal substrate 
yielded negative results. In the tests performed 
by Lehner [59] and by Donatsky and Dabelsteen 
[77], specific immunofluorescent localization was 
limited to the intracytoplasmic portion of the 
stratum spinosum cells . It is noteworthy that this 
is the site of epithelial damage in histopathologic 
specimens of early lesions of RAS. 
The study of Donatsky and Dabelsteen [77) is 
reminiscent of that of Bystryn, Abel, and Weid-
man [79], in which sera of several groups of 
patients , diluted 1:5, was reacted with human 
skin and a cytoplasmic fluorescence was obtained. 
These anticytoplasmic antibodies are fairly com-
mon; they occur in 1 of 6 normal persons, 1 of 5 
patients with various dermatoses , and 1 of 3 pa-
tients with cancer. The pathogenic significance of 
these antibodies is poorly understood, but they 
may represent a nonspecific immunologic reaction 
to chronic or recurrent epithelial tissue damage. 
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In vitro studies of lymphocytes harvested from 
patients with RAS add suggestive evidence to the 
thesis that cell-mediated immune responses to 
oral mucosal antigens are involved in the patho-
genesis of RAS . 
The lymphocyte transformation test is a means 
of detecting lymphocyte sensitization to a particu-
lar antigen [80]. Lymphocyte transformation tests 
[81] using a 1:50 dilution of a sterile saline homog-
enate of human fetal oral mucosa as antigen were 
positive in 10 of 19 patients with MiAu and MjAU 
and in 2 of 9 patients with HU. Lymphoblast 
transformation was negative when the disease 
was inactive but became positive with recrudesc-
ence of the aphthae in 1 patient who was followed 
sequentially. The antigen used in this study was 
crude, but 12 normal controls and 13 controls with 
miscellaneous oral ulcerative disorders showed 
negative results. In 5 of 9 patients with BS, the 
lymphoblast transformation tests a lso were posi-
tive [81]. Donatsky [72,73] has demonstrated a 
similar cellular response to adult human oral 
mucosal antigen and its correlation with disease 
activity. 
Lymphocyte cytotoxicity for target cells is an-
other method of evaluating specific lymphocyte 
sensitization [82]. The presence of lymphocyte 
cytotoxicity in vitro for colonic target cells in IBD 
[83,84] and muscle target cells in polymyositis 
[85-87], and the lymphocyte transformation stud-
ies in RAS and BS [81], led Dolby [88) to evaluate 
the lymphocytes of patients with RAS by cytotox-
icity assays on gingival epithelial target cells. 
This author demonstrated that the peripheral 
blood lymphocytes of 7 patients with MiAU re-
duced the survival in vitro of gingival target cells 
when compared with controls. This lymphocyto-
toxicity was blocked by preincubation of the lym-
phocytes of patients with RAS with rabbit antihu-
man lymphocytic serum [89]. Recently, Dolby [90] 
demonstrated that lymphocytes of patients with 
RAS are not cytotoxic for colonic epithelial target 
cells when incubated for 24 hours at a ratio of 5 
lymphocytes to 1 target cell and that hydrocorti-
sone succinate sodium (100 ~-tg/ml) blocked the 
cytotoxic activity of the aggressor lymphocytes 
when this agent was added to the in vitro short-
term culture medium [91]. 
Rogers, Sams, and Shorter [92] have previously 
described lymphocytotoxicity for gingival epithe-
lial target cells as measured by exclusion of the 
supravital dye trypan blue. This property of pe-
ripheral blood lymphocytes harvested from pa-
tients with RAS and BS was not noted when 
studying 14 normal subjects, 11 disease controls 
without oral lesions, and 10 disease controls with 
oral lesions. Movius, Rogers, and Reeve [93] also 
have demonstrated an increased lymphocytotoxic-
ity of peripheral blood lymphocytes of patients 
with destructive periodontal disease for gingival 
epithelial target cells when compared with peri-
odontal disease-free patients' lymphocytes. Re-
cently, Rogers, Movius, and Pierre [94] confirmed 
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and extended these observations with a second 
method to demonstrate target cell death. 
In vitro cell-mediated cytotoxicity mechanisms 
can be separated by the character of the effector 
cell and the dependence of the reaction on anti-
body [95,96). For example, immunization of a 
laboratory animal with nucleated allogeneic cells 
induces a population of lymphomononuclear cells 
capable of in vitro cytolysis of the immunogen, 
the nucleated allogeneic cell. The effector cells 
apparently are T lymphocytes, and the cytotoxic-
ity is antibody-independent [95]. Another cytotox-
icity system, the ADCC system [96,97], utilizes 
effector cells that may not have been specifically 
sensitized to attack target cells coated with anti-
body directed against their own cellular surface 
determinants. Cells bearing Fe receptors are ca-
pable of effecting the damage in this system (killer 
or K cells) . 
These observations of immunologic investiga-
tions of RAS may represent secondary phenom-
ena. The pathogenic relationship of these in vitro 
studies to the in vivo situation remains to be 
demonstrated. The elegant studies of self-toler-
ance and autoimmunity with respect to thyroid 
disease as reviewed by Allison [61] and the inves-
tigations of Stobo et al [53] and Shorter et a l [84] 
with respect to IBD are examples of pathways of 
investigation which may be fruitful with respect 
to an immunopathogenesis for RAS, as would the 
development of an animal model for RAS. 
SUMMARY AND CONCLUSIONS 
The heterogeneity of RAS is beginning to be 
appreciated, and subpopulations are being defined 
which may allow a more efficacious therapeutic 
approach to RAS. Clinical studies purporting to 
demonstrate therapeutic efficacy will be difficult 
to conduct because of the variable duration and 
frequency of lesions and the pain reduction that 
naturally attends the covering of the ulcer by the 
fibromembranous slough. 
The evidence for an immunopathogenesis for 
RAS is based on clinical and pathologic observa-
tions that lend credence to the thesis. These obser-
vations are becoming better founded as the asso-
ciated diseases are studied more intensively and 
the subpopulations of RAS sufferers are better 
defined. 
Evidence for a lymphocyte-epithelial cell inter-
action that may have pathogenetic significance 
can be gleaned from the pathologic features of 
early lesions, the evidence by lymphocyte trans-
formation tests, lymphocytotoxicity tests, and leu-
kocyte migration tests for sensitization of the 
lymphocyte (or the target cell), and the presence 
of antimucosal antibodies as an indication of im-
munologic reaction to epithelial tissue damage. 
Antigens such as the S. sanguis 2A microorgan-
ism and the oral mucosal saline homogenates and 
epithelial cells require purification. Sequential 
studies utilizing these antigens are necessary to 
correlate the immunologic reactivity with the dis-
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ease activity. Cross-reactivity between the oral 
mucosal and streptococcal 2A antigens requires 
study. 
Specific immunopathologic mechanisms can be 
better defined by utilizing the sophisticated im-
munologic techniques that have been developed 
in recent years. Further elucidation of these mech-
anisms and their role in the pathogenesis of RAS 
may provide a more rational approach to therapy 
for this common disorder. 
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